Cover Image
市場調查報告書

全身性紅斑性狼瘡 (SLE) 治療藥的全球市場:2015年∼2019年

Global Systemic Lupus Erythematosus (SLE) Drugs Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 328872
出版日期 內容資訊 英文 83 Pages
訂單完成後即時交付
價格
Back to Top
全身性紅斑性狼瘡 (SLE) 治療藥的全球市場:2015年∼2019年 Global Systemic Lupus Erythematosus (SLE) Drugs Market 2015-2019
出版日期: 2015年04月22日 內容資訊: 英文 83 Pages
簡介

全球全身性紅斑性狼瘡 (SLE) 治療藥的市場預計從2014年到2019年以22.41%的年複合成長率成長。

本報告提供全身性紅斑性狼瘡 (SLE) 治療藥的市場相關調查、市場及主要產品概要、疾病概要、開發平台狀況、各藥物類型、藥物類別、地區的市場分析、市場規模的變化與預測、市場成長的各種影響因素分析、競爭環境與市場佔有率,以及主要企業的簡介等彙整。

第1章 摘要整理

第2章 簡稱一覽

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 市場調查手法

第5章 簡介

第6章 疾病概要

第7章 SLE治療藥的開發平台狀況

第8章 市場環境

  • 市場概要
  • 市場規模、預測
  • 南北美洲
    • 市場規模、預測
  • 歐洲
    • 市場規模、預測

第9章 Benlysta:市場評估

  • 收益預測:美國
  • 收益預測:歐盟5國
  • 波特的五力分析

第10章 各類型市場

第11章 各類藥物市場

第12章 各地區市場

第13章 購買標準

第14章 市場成長推動要素

第15章 推動要素與其影響

第16章 市場課題

第17章 推動要素及課題的影響

第18章 市場趨勢

第19章 趨勢與其影響

第20章 供應商環境

  • 競爭模式
    • 主要消息
    • M&A
  • 市場佔有率分析
    • Anthera Pharmaceuticals
    • BMS
    • GSK
    • ImmuPharma
    • Merck Serono
    • UCB
  • 其他卓越供應商

第21章 主要供應商分析

  • Anthera Pharmaceuticals
  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • ImmuPharma
  • Merck Serono
  • UCB
    • 主要資料
    • 產業概要
    • 各部門收益
    • 各地區收益
    • 產業策略
    • 近幾年的發展趨勢
    • SWOT分析等

第22章 相關報告

圖表

目錄
Product Code: IRTNTR5703

About SLE

SLE is the most common form of lupus and is also called lupus. It is a chronic, autoimmune disease with signs and symptoms that can last for six months or for many years. It can affect any part of the body, such as the skin, joints, and organs (LFA, 2012). SLE occurs when the immune system produces autoantibodies, which attack and destroy healthy tissues in the body rather than foreign infectious agents. These autoantibodies cause inflammation, pain, and damage. It is also known as a disease of flare-ups and remissions and can range from mild to life threatening in severity. No cure for SLE yet exists.

TechNavio's analysts forecast the Global SLE Drugs market to grow at a CAGR of 22.41 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global SLE Drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of SLE that are available in the market.

TechNavio's report, the Global SLE Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA; it covers the Global SLE Drugs market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Anthera Pharmaceuticals
  • BMS
  • GSK
  • ImmuPharma
  • Merck Serono
  • UCB

Other Prominent Vendors

  • Amgen
  • HGS
  • Immunomedics
  • Johnson & Johnson
  • MedImmune
  • Sanofi
  • Teva Pharmaceutical Industries

Market Driver

  • High Prevalence of Autoimmune Disease
  • For a full, detailed list, view our report

Market Challenge

  • Complex Etiology
  • For a full, detailed list, view our report

Market Trend

  • Increase in Awareness
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market overview
  • 03.2. Product offerings

04. Market Research Methodology

  • 04.1. Market research process
  • 04.2. Research methodology

05. Introduction

06. Disease Overview

  • 06.1. Etiology
  • 06.2. Epidemiology
  • 06.3. Risk factors
  • 06.4. Quality of life
  • 06.5. Symptoms
  • 06.6. Diagnosis
  • 06.7. Management and treatment

07. SLE Pipeline Landscape

08. Market Landscape

  • 08.1. Market overview
  • 08.2. Market size and forecast
  • 08.3. SLE drugs market in Americas
    • 08.3.1. Market size and forecast
  • 08.4. SLE drugs market in Europe
    • 08.4.1. Market size and forecast

09. Market Assessment of Benlysta

    • 09.1.1. Benlysta revenue forecast in US
    • 09.1.2. Benlysta revenue forecast in 5EU
  • 09.2. Five forces analysis

10. Market Segmentation by Type

11. Market Segmentation by Therapeutic Class

12. Geographical Segmentation

13. Buying Criteria

14. Market Growth Drivers

15. Drivers and their Impact

16. Market Challenges

17. Impact of Drivers and Challenges

18. Market Trends

19. Trends and their Impact

20. Vendor Landscape

  • 20.1. Competitive scenario
    • 20.1.1. Key news
    • 20.1.2. Mergers and acquisitions
  • 20.2. Market share analysis 2014
    • 20.2.1. Anthera Pharmaceuticals
    • 20.2.2. BMS
    • 20.2.3. GSK
    • 20.2.4. ImmuPharma
    • 20.2.5. Merck Serono
    • 20.2.6. UCB
  • 20.3. Other prominent vendors

21. Key Vendor Analysis

  • 21.1. Anthera Pharmaceuticals
    • 21.1.1. Key facts
    • 21.1.2. Business overview
    • 21.1.3. Business strategy
    • 21.1.4. Recent developments
    • 21.1.5. SWOT analysis
  • 21.2. Bristol-Myers Squibb
    • 21.2.1. Key facts
    • 21.2.2. Business overview
    • 21.2.3. Key product offerings
    • 21.2.4. Revenue by geography
    • 21.2.5. Business strategy
    • 21.2.6. Key information
    • 21.2.7. SWOT analysis
  • 21.3. GlaxoSmithKline
    • 21.3.1. Key facts
    • 21.3.2. Business overview
    • 21.3.3. Business segmentation
    • 21.3.4. Business segmentation by revenue 2012 and 2013
    • 21.3.5. Sales by geography
    • 21.3.6. Pipeline products
    • 21.3.7. Business strategy
    • 21.3.8. Key information
    • 21.3.9. SWOT analysis
  • 21.4. ImmuPharma
    • 21.4.1. Key facts
    • 21.4.2. Business overview
    • 21.4.3. Business strategy
    • 21.4.4. Recent developments
    • 21.4.5. SWOT analysis
  • 21.5. Merck Serono
    • 21.5.1. Key facts
    • 21.5.2. Business overview
    • 21.5.3. Geographical segmentation by revenue 2013
    • 21.5.4. Business strategy
    • 21.5.5. Recent developments
    • 21.5.6. SWOT analysis
  • 21.6. UCB
    • 21.6.1. Key facts
    • 21.6.2. Business overview
    • 21.6.3. Product segmentation by revenue 2013
    • 21.6.4. Product segmentation by revenue 2012 and 2013
    • 21.6.5. Geographical segmentation by revenue 2013
    • 21.6.6. Business strategy
    • 21.6.7. Recent developments
    • 21.6.8. SWOT analysis

22. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market research methodology
  • Exhibit 2: Diagnosed prevalent cases of SLE 2014 and 2019
  • Exhibit 3: Overview of management of SLE
  • Exhibit 4: Global SLE drugs market 2014-2019 ($ million)
  • Exhibit 5: SLE drugs market in Americas 2014-2019 ($ million)
  • Exhibit 6: SLE drugs market in Europe 2014-2019 ($ million)
  • Exhibit 7: Benlysta: Global revenue 2011-2013 ($ million)
  • Exhibit 8: Benlysta: Revenue forecast in US 2014-2019 ($ million)
  • Exhibit 9: Benlysta: Revenue forecast in 5EU 2014-2019 ($ million)
  • Exhibit 10: Segmentation of global SLE drugs market by type
  • Exhibit 11: Segmentation of global SLE drugs market by therapeutic class
  • Exhibit 12: Segmentation of global SLE drugs market by geography 2014
  • Exhibit 13: Orencia: Global revenue 2011-2013 ($ million)
  • Exhibit 14: Bristol-Myers Squibb Co.: Key Product Offerings (Based on Therapeutic Areas)
  • Exhibit 15: Bristol-Myers Squibb: Revenue by geographical segmentation 2013
  • Exhibit 16: GlaxoSmithKline: Business segmentation 2013
  • Exhibit 17: GlaxoSmithKline: Business segmentation by revenue 2012 and 2013 (US$ billion)
  • Exhibit 18: GlaxoSmithKline: Sales by geography 2013
  • Exhibit 19: GlaxoSmithKline: Pipeline products 2013
  • Exhibit 20: Merck Serono: Geographical segmentation by revenue 2013
  • Exhibit 21: UCB: Product segmentation by revenue 2013
  • Exhibit 22: UCB: Product segmentation by revenue 2012 and 2013 (US$ million)
  • Exhibit 23: UCB: Geographical segmentation by revenue 2013
Back to Top